Recent share performance and business snapshot
Recursion Pharmaceuticals (RXRX) has drawn fresh attention after a recent pullback, with the stock closing at US$3.25 and posting negative returns over the past month and the past 3 months.
The company remains a clinical stage biotechnology player focused on drug discovery using data science and automation. It reported revenue of US$74.681 million and a net loss of US$644.759 million, with operations spanning the United States and the United Kingdom.
See our latest analysis for Recursion Pharmaceuticals.
That recent 1-day share price return of 3.56% decline and 90-day share price return of 25.46% decline sit alongside a 1-year total shareholder return of 52.14% loss. Together, these figures suggest momentum has been fading as investors reassess execution risks and funding needs.
If you are comparing Recursion with other names in this space, it can help to widen the lens and scan for 36 healthcare AI stocks
With RXRX trading at US$3.25, a value score of 2 and an indicated intrinsic discount of 65.59%, the key question is whether this weakness signals a potential entry point or whether the market is already factoring in future growth.
Most Popular Narrative: 65% Overvalued
The most followed narrative pegs Recursion Pharmaceuticals' fair value at US$1.97 per share compared with the last close at US$3.25, which sets up a sharp valuation gap for investors to examine.
RXRX is a terrible biotech only because the INSIDERS themselves don’t believe in it! All they’re doing is milking the heck out of this doomed stock! Never seen a company where ALL they’re doing insiders are selling! Stock continues to go down every month! CEO said in 2014 that in 10 years there would be 100 new drugs! 12 years later they have ZERO 0️⃣!!! This stock went from over $40 to under $4! The hype is unbelievable! Worst biotech ever!!! Nuff said
This narrative leans heavily on insider selling, past share price swings and unmet product expectations. It treats those ingredients as the core drivers behind the overvaluation call, not the current revenue line or future margin assumptions.
Result: Fair Value of $1.97 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, insider sentiment could shift, and progress across REC-4881, REC-617 or other clinical programs, plus existing big pharma collaborations, may challenge such a bearish view.
Find out about the key risks to this Recursion Pharmaceuticals narrative.
Another view on fair value
The most popular community view tags RXRX as overvalued at a fair value of US$1.97, but the SWS DCF model points the other way, with a fair value estimate of US$9.45 against the current US$3.25 share price. That gap suggests a very different story, so which signal do you trust more?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 54 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment clearly split between risk and reward, this is a moment to move quickly. Review the underlying numbers yourself and weigh both sides using our breakdown of 2 key rewards and 3 important warning signs
Looking for more investment ideas?
If RXRX is on your radar, do not stop there. Broaden your watchlist with focused stock ideas that match the kind of opportunities you care about most.
- Target potential mispricings by scanning for companies that combine quality with attractive entry prices through the 54 high quality undervalued stocks
- Prioritise resilience by checking out the 72 resilient stocks with low risk scores and focus on businesses with lower overall risk profiles than the wider market.
- Hunt for future standouts early via the screener containing 26 high quality undiscovered gems and spot strong fundamentals before they are widely talked about.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com